Goldman Sachs Starts Thoratec (THOR) at Neutral
Tweet
Share
E-mailGet Alerts THOR Hot Sheet
Price: $26.43 +0.38%
Rating Summary:
8 Buy, 16 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 16 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs initiates coverage on Thoratec (NASDAQ: THOR) with a Neutral. PT $33.00.
Over the long-term Goldman expects the company's core technology has the potential to be one of the most significant markets in MedTech. That said, "new competition in the US, a lack of major new products in 2012, and the need to invest in market development will likely cap the potential for upside."
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $30.44 yesterday.
Over the long-term Goldman expects the company's core technology has the potential to be one of the most significant markets in MedTech. That said, "new competition in the US, a lack of major new products in 2012, and the need to invest in market development will likely cap the potential for upside."
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $30.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
